CDC surveillance and short-window probability

CDC surveillance data make this clear. Since 1993, the United States has recorded 890 laboratory-confirmed hantavirus cases (through end-2023), averaging roughly 28 to 30 cases per year (range 20 to 40 in most recent decades). This equates to an expected rate of approximately 0.077 to 0.082 cases per day nationwide. Over the market’s roughly 8.5-day window (May 7 to May 15), the expected number of cases (λ) is therefore about 0.65 to 0.70. Under a simple Poisson process for rare events, that implies a roughly 48% to 51% probability of at least one confirmed-and-reported case, even before any seasonal or 2026-specific adjustments.

The market’s implicit pricing (presumably well below 40% for YES as of May 8 to 9) appears to reflect fixation on the cruise-ship monitoring of about 7 to 17 asymptomatic U.S. returnees. That is understandable but statistically misplaced for this short horizon. The Andes virus incubation period is 1 to 8 weeks (typically 2 to 4), and even urgent symptomatic testing plus CDC/state lab confirmation still takes 3 to 10 or more days. The chance of a cruise-linked U.S. case clearing all those hurdles and appearing in official CDC/NNDSS reporting by May 15 is negligible (about 5% to 10% at most). That leaves the vast majority of the probability mass coming from ordinary domestic exposures: rodent contact in the rural West and Southwest, which are the source of nearly all U.S. cases historically.

CDC data further support elevating the baseline probability in this specific window:

Seasonality strongly favors May

Historical onset-month distributions (1993 to 2009 CDC analysis, and consistent in later surveillance) show the peak number of cases occurs in May, June, and July, with the fewest in December through February. Roughly 40% to 45% of all U.S. cases cluster in those three spring/summer months. We are sitting squarely inside the highest-risk period of the calendar year.

2026 year-to-date pattern is consistent with background noise, not a lull

As of NNDSS Week 15 (ending April 18, 2026), CDC provisional tables showed only 3 total hantavirus infections YTD (2 HPS + 1 non-HPS). An additional domestic case was publicly reported in northern Nevada at the end of April. This low early-year count is well within normal variation and does not signal any suppression of the underlying rate; if anything, the spring ramp-up is now underway.

Reporting mechanics do not create a hard barrier

While full confirmation can take days to weeks, cases with symptom onset in late April (perfectly plausible given the May peak) can, and historically do, reach state labs and CDC notification within the first half of May. The NNDSS weekly stack tables themselves are provisional and frequently revised upward in subsequent weeks, meaning a case that meets lab criteria in the next 7 days has a realistic shot at entering credible reporting (CDC or overwhelming news consensus) before the May 15 cutoff.

In short, the YES outcome does not require an exotic cruise-ship breakthrough. It only requires one of the roughly 20 to 40 routine domestic hantavirus infections that the CDC has documented every year for the past three decades to happen to clear the confirmation pipeline in this particular 8-day slice, something the raw incidence rate and May seasonality suggest is essentially a coin-flip proposition (about 45% to 55% true probability when you layer in the seasonal boost). If the market is pricing YES materially below that level because attention is glued to the cruise-ship story, then YES is undervalued by a clear margin. The background rodent-driven risk, per long-term CDC NNDSS data, is simply too consistent to ignore in a window this short.